Skip to main content

No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 22, 2025.

via HealthDay

WEDNESDAY, Jan. 22, 2025 -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online Jan. 16 in Thyroid.

Sarah M. Baxter, from Queen’s University Belfast in Northern Ireland, and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated with thyroid cancer risk in patients with type 2 diabetes. The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3.0 years.

The researchers found that GLP-1 RA use was not associated with an increased risk for thyroid cancer (pooled weighted hazard ratio, 0.81; 95 percent confidence interval, 0.59 to 1.12) compared with use of DPP-4i. Among GLP-1 RA ever-users, there was no increased risk in thyroid cancer with an increasing cumulative dose of GLP-1 RA.

"In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP-1 RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8 to 3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs," the authors write. "Nevertheless, evidence was insufficient to rule out excess risk with long-term use, due to the short follow-up."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Weight Loss Continues Five Years After Tummy Tucks

THURSDAY, July 3, 2025 -- Patients undergoing abdominoplasty experience continued weight loss up to five years postoperatively, according to a study published in the July issue...

2011 to 2023 Saw Increase in Prevalence of Obesity Among Children

WEDNESDAY, July 2, 2025 -- The prevalence of obesity increased among children and adolescents from 2011 to 2023, with the increase most pronounced among Black youths, according to...

Thresholds for Preop Serum Calcitonin Predict Lymph Node Metastasis in Thyroid Cancer

WEDNESDAY, July 2, 2025 -- Updated threshold values of preoperative serum calcitonin predict different extents of lymph node metastasis (LNM) in patients with medullary thyroid...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.